Exercise-induced lactic acidemia associated with a SLC16A13 biallelic variant Authors: Narin Intarak, Sasiprapa Prommanee, Thanakorn Theerapanon, Worawan Sirichana, Onanong Kulaputana, Vichit Supornsilchai, Atsushi Ohazama, Katsushige Kawasaki, Paul T. Sharpe, Thitaya Chaiboonyarak, Vorasuk Shotelersuk, Thantrira Porntaveetus Published: 2026 ABSTRACT The molecular basis of impaired lactate clearance and exercise-induced lactic acidemia remains largely unknown. Here, we report a 10-year-old Thai girl, born to consanguineous parents, with growth delay and partial growth hormone deficiency. The proband underwent detailed clinical phenotyping, exercise stress testing, metabolic profiling, and genome sequencing. She presented with profound exercise-induced lactic acidemia, characterized by elevated blood lactate (3.7-fold above baseline) and severely compromised clearance. Genome sequencing identified a novel homozygous frameshift variant in the solute carrier gene SLC16A13 (c.24delC, p.Asp9Thrfs*50). To assess causality, Slc16a13 knockout mice were generated and subjected to treadmill exercise and biochemical assays, revealing impaired decline of blood lactate after exercise (p = 0.001) and altered amino acid metabolism. These findings implicate SLC16A13 as a critical regulator of lactate metabolism in humans and establish a direct link between biallelic SLC16A13 variants and exercise-induced lactic acidemia, highlighting a novel genetic mechanism underlying exercise stress and metabolic dysregulation. Introduction Lactic acidosis is a metabolic condition defined by the accumulation of lactate in the bloodstream, leading to a decrease in physiological pH. Lactate is a normal byproduct of anaerobic glycolysis, a metabolic pathway that generates energy in the absence of sufficient oxygen. While often historically viewed as a metabolic waste product, lactate is now understood to be a crucial carbohydrate fuel source that is shuttled between cells and tissues. The body, particularly the liver and kidneys, typically clears lactate efficiently. However, when lactate production overwhelms its clearance, lactic acidosis can develop1. This condition can be triggered by various factors, including severe illness2, which can cause tissue hypoxia (Type A lactic acidosis), or by underlying diseases and certain medications where tissue oxygenation is not overtly impaired (Type B lactic acidosis)3–7. Common symptoms are nonspecific and can include intense weakness, fatigue, nausea, and rapid breathing8. Therefore, lactic acidosis serves as an important, albeit general, indicator of underlying metabolic distress that requires prompt medical evaluation to identify and treat the root cause. A key process in lactate clearance is the Cori cycle, a metabolic loop between the muscles and the liver. During intense exercise, muscles produce lactate via anaerobic glycolysis. This lactate is released into the bloodstream, transported to the liver, and converted back into glucose through gluconeogenesis1. This newly formed glucose can then be returned to the muscles for energy, thus completing the cycle and preventing the excessive buildup of lactate. The movement of lactate across cell membranes is critical for both its release from producing tissues and its uptake for utilization in tissues like the liver, heart, and oxidative muscle fibers. This transport is facilitated by a family of proton-linked monocarboxylate transporters (MCTs), which belong to the solute carrier 16A (SLC16A) family9. Among the 14 known MCTs, isoforms 1–4 have been the most extensively studied10. MCT1 (SLC16A1) is widely expressed and is particularly abundant in tissues with high oxidative capacity, where it primarily facilitates lactate uptake11. MCT4 (SLC16A3) is predominantly found in glycolytic tissues, such as fast-twitch muscle fibers, and is responsible for lactate efflux. The expression and density of both MCT1 and MCT4 in skeletal muscle can be increased through exercise training, enhancing lactate clearance and metabolic efficiency. MCT2 (SLC16A7) exhibits a high affinity for lactate and is involved in its uptake in tissues like the liver and kidneys10. MCT3 (SLC16A8) has a more restricted expression, primarily in the retinal pigment epithelium10. Recently, another member of this family, SLC16A13 (MCT13), has been identified as a high-affinity lactate transporter12. While genome-wide association studies have linked the SLC16A13 gene to type 2 diabetes, its precise physiological role has been largely unknown13. Studies in knockout mice have shown that the loss of Slc16a13 impairs hepatic lactate transport and utilization12. This leads to reduced substrate availability for gluconeogenesis and has been shown to protect mice from diet-induced insulin resistance and fatty liver disease12. Although primarily expressed in the liver, kidney, and colon, some research suggests it may also function as an oligopeptide transporter in the intestine14. To date, no human disease has been directly attributed to variants in the SLC16A13 gene. This study presents the first clinical evidence of a potential association between biallelic SLC16A13 gene variants and exercise-induced lactic acidosis in a human subject. Our findings are further substantiated by functional data from Slc16a13 knockout mice, which demonstrate impaired decline of blood lactate under metabolic stress, thereby providing a potential mechanistic link for this novel clinical observation. Results Endocrine evaluation and diagnosis of idiopathic short stature The proband is a 10-year-old Thai girl, the firstborn child of consanguineous parents (Fig. 1a). She was born full term via Cesarean section with an imperforate anus, which was surgically corrected during the neonatal period. At the age of 8, she was referred for endocrine evaluation due to concerns about growth failure. Her height was 113 cm (<3rd percentile) and her weight was 23 kg (3rd percentile) (Fig. 1b).Fig. 1Family pedigree, growth chart, hand radiographs for bone age, and variant analysis of the proband.a A family pedigree. The arrow indicates the proband. The black symbol indicates subjects with partial growth hormone deficiency, congenital imperforated anus, and anodontia. b A growth chart with the area between the vertical dashed lines indicating the admission period. Blue dots indicate height or weight. The red dots represent bone age. The black dot indicates mid-parental height, and the solid vertical black line shows the target height range (149.5–163.5 cm). c Hand radiograph. The bone age was determined from the left radiograph. d Chromatograms demonstrate the homozygous variant of c.24delC, p.Asp9Thrfs*50) in SLC16A13 in IV:1(proband) but not in III: 3, III: 7, and IV: 3. The red arrow indicates c.24delC. e Conservation of Asp5 among different species is highlighted in green. Family pedigree, growth chart, hand radiographs for bone age, and variant analysis of the proband. a A family pedigree. The arrow indicates the proband. The black symbol indicates subjects with partial growth hormone deficiency, congenital imperforated anus, and anodontia. b A growth chart with the area between the vertical dashed lines indicating the admission period. Blue dots indicate height or weight. The red dots represent bone age. The black dot indicates mid-parental height, and the solid vertical black line shows the target height range (149.5–163.5 cm). c Hand radiograph. The bone age was determined from the left radiograph. d Chromatograms demonstrate the homozygous variant of c.24delC, p.Asp9Thrfs*50) in SLC16A13 in IV:1(proband) but not in III: 3, III: 7, and IV: 3. The red arrow indicates c.24delC. e Conservation of Asp5 among different species is highlighted in green. Initial investigations revealed a peak growth hormone (GH) level of 7.69 ng/mL following stimulation with clonidine and L-DOPA. Her insulin-like growth factor 1 (IGF-1) level was 113 ng/mL, which is below the age- and sex-matched median (reference range: 57–316 ng/mL; median: 134 ng/mL). Other baseline laboratory results, including thyroid function, liver enzymes, blood glucose, and a complete blood count, were all within normal limits. Imaging studies, including a brain/pituitary MRI and renal ultrasonography, were unremarkable. Based on these findings, she was diagnosed with idiopathic short stature. An additional clinical finding of high myopia was noted. At the age of 10 years and 6 months, she was referred to further genetic investigation to identify a potential underlying etiology for her clinical presentation. Treatment with recombinant GH was initiated at a dose of 0.045 mg/kg/day when the proband was 8 years old, supplemented with a multivitamin, chelated zinc, calcium, and vitamin D3. During the course of therapy, the GH dosage was titrated based on growth velocity and to maintain serum IGF-1 levels within the upper-normal range. For instance, at 8 years of age, her IGF-1 level was 148 ng/mL, which was above the age-specific median. A significant improvement in growth parameters was observed during the treatment period. The GH therapy was discontinued at the age of 13 years and 4 months, at which point her bone age was determined to be 15 years. Her final adult height at age 15 was 151 cm (between the 10th and 25th percentiles), which is consistent with her genetic potential based on a mid-parental height of 156.5 cm (target height range: 149.5–163.5 cm), derived from parental heights of 176 cm (father) and 150 cm (mother). The proband’s pubertal and intellectual development proceeded normally for her age. Serial bone age assessments demonstrated a pattern of initial delay followed by acceleration, with readings as follows: 59/12–610/12 years at a chronological age of 8; 710/12 at age 9; 11 years at age 10 years 8 months; 12 years at age 12; and 14 years at age 13 years 4 months (Fig. 1c). At 15 years of age, a body composition analysis was conducted. The proband’s weight was 38.2 kg. Key parameters, including total body water (22.0 kg), mineral content (2.26 kg), body fat mass (8.2 kg), and body fat percentage (21.4%) were all within their respective reference ranges (21.7–26.5 kg, 2.01–2.45 kg, 7.0–13.9 kg, and 18-28%). However, her total protein mass was measured at 5.7 kg, which was marginally below the lower limit of the reference range (5.8–7.2 kg). Furthermore, her measured basal metabolic rate (BMR) was 1010 kcal/day, which is lower than her estimated minimum daily energy requirement of 1230 kcal/day. Despite these specific findings, her overall body mass index (BMI) was 16.8 Kg/m2 that was placed in between the 3rd and 15th percentile. Identification of a novel biallelic frameshift variant in SLC16A13 Genome sequencing of the proband identified a total of 4,559,141 variants. After applying a filtering strategy based on variant type, frequency, and predicted effect, we narrowed the candidates to four potentially pathogenic variants in the SLC16A13, ADAM8, KLF18, and SCYGR7 genes (Supplementary Table S1). A review of existing literature and gene functions revealed that while variants in SLC16A13 have been associated with type 2 diabetes12,13 and those in ADAM8 with cancer progression15, no definitive disease associations have been established for KLF18 and SCYGR7. Among these candidates, a novel homozygous frameshift variant in exon 1 of the SLC16A13 gene, c.24delC p.(Asp9Thrfs*50), emerged as the most compelling. This variant is predicted to cause a premature stop codon, leading to a truncated, non-functional protein. Crucially, this variant was absent from all public and internal population databases, including gnomAD, ESP, the Thai Reference Genome, and an in-house Thai exome, indicating its extreme rarity. Furthermore, to exclude the possibility that this metabolic impairment was compounded by additional genetic factors, such as mitochondrial dysfunction or alternative transporter defects, we expanded our genetic evaluation. We filtered the patient’s sequencing data using Human Phenotype Ontology (HPO) terms related to mitochondrial respiratory chain defects (HP:0200125) and congenital mitochondrial abnormalities (HP:0012103). Additionally, we screened for variants across the broader monocarboxylate transporter (MCT) gene family. No pathogenic variants or relevant polymorphisms were identified in these loci. This rigorous filtering reinforces our conclusion that the biallelic SLC16A13 variant is the primary genetic driver of the proband’s phenotype. The presence of the c.24delC variant was confirmed, and its segregation was analyzed using Sanger sequencing. This analysis revealed that the proband was homozygous for the variant, while both asymptomatic parents and her younger brother were heterozygous carriers, consistent with an autosomal recessive inheritance pattern (Fig. 1d). Analysis of evolutionary conservation showed that the affected amino acid residue, Aspartic acid at position 9, is highly conserved across multiple species, including chimpanzee, pig, dog, bovine, mouse, and zebrafish, highlighting its likely importance for protein function (Fig. 1e). Metabolic and exercise physiology assessment reveals abnormal lactate kinetics According to the proband’s medical record, plasma amino acid analysis performed at 13 years of age revealed slightly elevated levels of alanine, lysine, and proline. To further probe the proband’s metabolic response to physical stress, a constant load exercise test was performed at 15 years of age to assess lactate production and clearance dynamics16. Blood and urine samples were collected at baseline, during exercise, and during the recovery phase (Fig. 2a).Fig. 2Exercise tolerance test and proband blood tests.a Schematic diagram of the exercise tolerance test. The blood and urine are collected at desirable times, including before cycling (R0), during cycling (S5, S10, and S15) and after cycling (R1 and R2). The blood biochemistry analysis is determined as outlined in a diagram. b The level of proband’s blood lactate, ammonia, and CK at different time points is presented in a bar graph. c Blood lactate level of the proband is compared to healthy subjects and patients with mitochondriopathy (MCP) obtained from the previous study17. The data are presented as a relative fold change to before cycling (R0). After 10 minutes of rest before the test: R0, cycling for 5 min: S5, cycling for 10 min: S10, cycling for 15 min: S15, after cycling for 15 min: R1, after cycling for 30 min: R2. The black dashed line represents the maximum reference value of healthy subjects. The red and blue dashed lines depict the temporal evolution of lactate fold change for the MCP and the proband, respectively. d The urine organic acid analysis of the proband before and after cycling. Proband’s organic acid profiles obtained at 10 minutes before cycling (R0) and 15 minutes after exercise (R1). Rt, retention time. The red text indicates lactate-related metabolites. The blue text indicates an individual compound observed exclusively at R0 or R1. Exercise tolerance test and proband blood tests. a Schematic diagram of the exercise tolerance test. The blood and urine are collected at desirable times, including before cycling (R0), during cycling (S5, S10, and S15) and after cycling (R1 and R2). The blood biochemistry analysis is determined as outlined in a diagram. b The level of proband’s blood lactate, ammonia, and CK at different time points is presented in a bar graph. c Blood lactate level of the proband is compared to healthy subjects and patients with mitochondriopathy (MCP) obtained from the previous study17. The data are presented as a relative fold change to before cycling (R0). After 10 minutes of rest before the test: R0, cycling for 5 min: S5, cycling for 10 min: S10, cycling for 15 min: S15, after cycling for 15 min: R1, after cycling for 30 min: R2. The black dashed line represents the maximum reference value of healthy subjects. The red and blue dashed lines depict the temporal evolution of lactate fold change for the MCP and the proband, respectively. d The urine organic acid analysis of the proband before and after cycling. Proband’s organic acid profiles obtained at 10 minutes before cycling (R0) and 15 minutes after exercise (R1). Rt, retention time. The red text indicates lactate-related metabolites. The blue text indicates an individual compound observed exclusively at R0 or R1. At a constant intensity of 30 watts during cycling exercise, the proband’s blood lactate levels rose significantly above the normal range and remained elevated during the post-exercise recovery period, although they did show a decreasing trend (Fig. 2b and Table 1). These findings were consistent between central laboratory analysis and point-of-care testing. Specifically, compared to baseline (R0), the proband’s lactate concentrations increased by approximately 2.2-, 3.2-, and 3.7-fold at the 5-, 10-, and 15-min exercise stages (S5, S10, and S15), respectively. While the levels decreased during recovery, they did not return to baseline within the 30-min post-exercise window and remained above the established reference range (Fig. 2c).Table 1Blood biochemistry analysis of the proband after 10 minutes of rest before the test (R0), after 5 min (S5), 10 min (S10), and 15 min (S15) of cycling, and after 15 min (R1) and 30 min (R2) of rest following the testBlood testingUnitR0S5S10S15R1R2Reference rangePlasma glucosemg/dL9499939093ND80–100Lactate (mmol/L) (central lab)mmol/L1.40973.17464.51775.16153.25232.5530.4995–2.1978Lactate (mmol/L) (EDGE)mmol/L1.33.24.24.532.300.4995–2.1978Ammonia (ug/dL)ug/dL59767791555830–120CK (U/L)U/L10910910911010710129–168BUNmg/dL10NDNDND10ND7–20Creatininemg/dL0.56NDNDND0.51ND0.5–1.0SGOTU/L19NDNDND18ND5–35SGPTU/L7NDNDND8ND0–40ElectrolytesNammol/L139NDND140139ND136–145Kmmol/L3.7NDND4.43.8ND3.4–4.5Clmmol/L107NDND109106ND98–107HCO3mmol/L23NDND2021ND22–29AGAPmmol/L9NDND1112ND6.0–14.0Lipid profileCHOLmg/dL153NDNDND143ND<200TRIGmg/dL61NDNDND60ND>50HDLmg/dL45NDNDND42ND<150LDL-directmg/dL84NDNDND79ND<130 Table 1Blood biochemistry analysis of the proband after 10 minutes of rest before the test (R0), after 5 min (S5), 10 min (S10), and 15 min (S15) of cycling, and after 15 min (R1) and 30 min (R2) of rest following the testBlood testingUnitR0S5S10S15R1R2Reference rangePlasma glucosemg/dL9499939093ND80–100Lactate (mmol/L) (central lab)mmol/L1.40973.17464.51775.16153.25232.5530.4995–2.1978Lactate (mmol/L) (EDGE)mmol/L1.33.24.24.532.300.4995–2.1978Ammonia (ug/dL)ug/dL59767791555830–120CK (U/L)U/L10910910911010710129–168BUNmg/dL10NDNDND10ND7–20Creatininemg/dL0.56NDNDND0.51ND0.5–1.0SGOTU/L19NDNDND18ND5–35SGPTU/L7NDNDND8ND0–40ElectrolytesNammol/L139NDND140139ND136–145Kmmol/L3.7NDND4.43.8ND3.4–4.5Clmmol/L107NDND109106ND98–107HCO3mmol/L23NDND2021ND22–29AGAPmmol/L9NDND1112ND6.0–14.0Lipid profileCHOLmg/dL153NDNDND143ND<200TRIGmg/dL61NDNDND60ND>50HDLmg/dL45NDNDND42ND<150LDL-directmg/dL84NDNDND79ND<130 Blood biochemistry analysis of the proband after 10 minutes of rest before the test (R0), after 5 min (S5), 10 min (S10), and 15 min (S15) of cycling, and after 15 min (R1) and 30 min (R2) of rest following the test During the 15-min constant work rate cardiopulmonary exercise test at 30 W, the proband exhibited an adequate cardiopulmonary response (Fig. S1). Heart rate (HR) increased appropriately over the duration of the test. Oxygen pulse (VO2/HR), used as a surrogate for stroke volume, demonstrated a progressive rise followed by a plateau, consistent with an appropriate stroke volume response to the sustained workload (Fig. S1b). An anaerobic threshold (AT) was identifiable, as shown in Fig. S1c, there was a distinct inflection point at which VCO₂ began to increase more steeply relative to VO₂. This finding was corroborated by ventilatory equivalents: VE/VO₂ reached a nadir and subsequently increased, whereas VE/VCO₂ remained relatively stable (Fig. S1d). End-tidal CO₂ (PETCO₂) remained stable during mid-exercise and declined toward the end of the test, reflecting an expected compensatory ventilatory response to developing metabolic acidosis. Peripheral oxygen saturation (SpO₂) remained stable at ~95–97% throughout exercise (Fig. S1e, f). The respiratory exchange ratio17,18 exceeded 1.10 at peak exercise, indicating a high level of metabolic stress and supporting that the proband achieved near-maximal effort (Fig. S1g). Overall, the proband demonstrated normal aerobic capacity and reached a state of metabolic acidosis (RER >1.1) with no overt signs of cardiovascular or respiratory systems. Because the adequate cardiopulmonary response excludes lactate overproduction secondary to hypoxemia, the pronounced upward lactate trajectory and delayed recovery strongly suggest impaired lactate clearance. In contrast to the lactate findings, blood ammonia concentrations, which also increased during exercise (S5, S10, and S15), stayed within the normal reference interval. These levels promptly returned to baseline within 15 min of concluding the exercise (R1) (Fig. 2b and Table 1). In addition to blood ammonia, creatine kinase (CK) activity, a marker of muscle damage, remained within the reference range throughout the entire test. To provide a comparative context for the lactate findings, the proband’s results were benchmarked against a standardized lactate stress test protocol previously described by Finsterer and Milvay for a cohort of 155 patients with mitochondriopathy (MCP) and 62 healthy controls16. This comparison revealed that the fold change in lactate concentration from baseline was more pronounced in the proband than in both the MCP and the healthy control groups (Fig. 2c). While the general trend of a gradual increase in lactate during exercise followed by a decline in recovery was similar across all groups, the magnitude of the proband’s lactate response was notably greater. During constant-load exercise at an intensity close to the maximal lactate steady state (MLSS), a delay may occur before lactate production and clearance reach equilibrium, resulting in a sustained elevation of blood lactate concentration, as demonstrated by the MCP patient and healthy in Fig. 2c. Unexpectedly, the proband exhibited a prolonged in attaining MLSS compared to the MCP. This finding is further indicative of impaired lactate clearance. Other standard blood chemistry panels, including glucose, blood urea nitrogen (BUN), creatinine, liver enzymes (SGOT, SGPT), electrolytes (Na, K, Cl, HCO3), the anion gap, and a lipid profile (cholesterol, triglycerides, HDL, and LDL), were all within their respective reference ranges (Table 1). Comprehensive metabolic profiling reveals exercise-induced perturbations in organic acids, amino acids, and fatty acid metabolism To further delineate the metabolic impact of the patient’s condition, a comprehensive analysis of urine organic acids, plasma amino acids, and acylcarnitine profiles was performed at baseline (R0) and immediately following the exercise test (R1). Urine organic acid analysis: Analysis of the R1 urine sample revealed significant changes compared to the R0 sample. An increased concentration of propionic acid, which can be linked to lactate metabolic pathways, was noted. Furthermore, several dicarboxylic acids, including propanedioic (malonic), pentanedioic (glutaric), and 2-pentenedioic acid, were detected exclusively in the post-exercise sample, suggesting a metabolic shift and potential overload of fatty acid oxidation pathways in response to exercise stress (Fig. 2d). Plasma amino acid profiling: At R0, the proband’s plasma amino acid profile showed elevations in several key amino acids, including alanine, asparagine, citrulline, ornithine, and taurine, while cystine levels were marginally below the reference range (Table 2). At R1, a dynamic shift was observed: alanine, asparagine, and ornithine concentrations returned to within the normal range. Notably, citrulline levels decreased sharply to below the limit of detection. In contrast, taurine remained elevated post-exercise.Table 2Plasma amino acid profiles analysis of the proband at 15 years oldAmino acidsAbbreviationsResults (nmole/ mL plasma)Reference range 2–17 year-old (nmole/ mL plasma)R0R11-Methyl histidine1-MhisBDLBDL≤273-Methyl histidine3-MhisBDLBDL1–6AlanineAla538.63390.69157–481AnserineAnsBDLBDL-ArginineArg74.2188.9438–122AsparagineAsn75.657.8423–70Aspartic acidAsp6.068.321–8CarnosineCarBDLBDL-CitrullineCit85.52BDL9–52CystathionineCysthBDLBDL<1CystineCys23.4725.1524–52EthanolamineEthanBDLBDL5–15Glutamic acidGlu80.3383.599–109GlutamineGln397.14383.78405–923GlycineGly283.4207.81138–349HistidineHis41.6239.9354–113HomocystineHomocysBDLBDL<1HydroxylysineHylysBDLBDL-HydroxyprolineHyproBDLBDL6–32IsoleucineIle66.8256.3433–97LeucineLeu119.18105.6665–179LysineLys207.63185.3998–231MethionineMet20.4719.3214–37OrnithineOrn137.85101.6833–103PhenylalaninePhe41.8737.7738–86PhosphoethanolaminePeaBDLBDL-PhosphoserinePhserBDLBDL-ProlinePro201.1212.6499–351SarcosineSarcBDLBDL≤4SerineSer174.53166.8685–185TaurineTaur230.31217.9132–114ThreonineThr175.66163.7659–195TryptophanTrpBDLBDL30–94TyrosineTyr60.5654.7931–108ValineVal235.59220.21130–307α-Aminoadipic acidAAAABDLBDL≤2α-Aminobutyric acidAabaBDLBDL6–30β-alanineB-AlaBDLBDL≤5β-Aminoisobutyric acidAibaBDLBDL≤6γ-Aminobutyric acidGabaBDLBDL≤2R0 At rest - 10 min before the cycling test, R1 after finishing cycling at 15 min, BDL below detection limit.Bold numbers indicate values above the reference values. Table 2Plasma amino acid profiles analysis of the proband at 15 years oldAmino acidsAbbreviationsResults (nmole/ mL plasma)Reference range 2–17 year-old (nmole/ mL plasma)R0R11-Methyl histidine1-MhisBDLBDL≤273-Methyl histidine3-MhisBDLBDL1–6AlanineAla538.63390.69157–481AnserineAnsBDLBDL-ArginineArg74.2188.9438–122AsparagineAsn75.657.8423–70Aspartic acidAsp6.068.321–8CarnosineCarBDLBDL-CitrullineCit85.52BDL9–52CystathionineCysthBDLBDL<1CystineCys23.4725.1524–52EthanolamineEthanBDLBDL5–15Glutamic acidGlu80.3383.599–109GlutamineGln397.14383.78405–923GlycineGly283.4207.81138–349HistidineHis41.6239.9354–113HomocystineHomocysBDLBDL<1HydroxylysineHylysBDLBDL-HydroxyprolineHyproBDLBDL6–32IsoleucineIle66.8256.3433–97LeucineLeu119.18105.6665–179LysineLys207.63185.3998–231MethionineMet20.4719.3214–37OrnithineOrn137.85101.6833–103PhenylalaninePhe41.8737.7738–86PhosphoethanolaminePeaBDLBDL-PhosphoserinePhserBDLBDL-ProlinePro201.1212.6499–351SarcosineSarcBDLBDL≤4SerineSer174.53166.8685–185TaurineTaur230.31217.9132–114ThreonineThr175.66163.7659–195TryptophanTrpBDLBDL30–94TyrosineTyr60.5654.7931–108ValineVal235.59220.21130–307α-Aminoadipic acidAAAABDLBDL≤2α-Aminobutyric acidAabaBDLBDL6–30β-alanineB-AlaBDLBDL≤5β-Aminoisobutyric acidAibaBDLBDL≤6γ-Aminobutyric acidGabaBDLBDL≤2R0 At rest - 10 min before the cycling test, R1 after finishing cycling at 15 min, BDL below detection limit.Bold numbers indicate values above the reference values. Plasma amino acid profiles analysis of the proband at 15 years old R0 At rest - 10 min before the cycling test, R1 after finishing cycling at 15 min, BDL below detection limit. Bold numbers indicate values above the reference values. Plasma acylcarnitine profiling: The R0 acylcarnitine profile, which reflects fatty acid and amino acid oxidation intermediates, indicated elevations in free carnitine (C0), adipylcarnitine (C6DC; a dicarboxylic acid carnitine), and hexadecanoylcarnitine (C16; a long-chain acylcarnitine). Post-exercise (R1), C0 and C6DC remained elevated, whereas C16 normalized. The majority of other acylcarnitine species exhibited a decrease in concentration at R1 compared to their baseline levels (Supplementary Table S2), a finding consistent with their utilization during acute exercise. Functional validation in a murine model reveals impaired lactate clearance following exercise Given that SLC16A13 is implicated in hepatic lactate transport for gluconeogenesis, we hypothesized that its absence would impair systemic lactate clearance. To functionally test this hypothesis and investigate the pathogenic mechanism of the identified human variant, we generated a homozygous Slc16a13 knockout (KO) mouse model using CRISPR/Cas9 technology (Fig. 3a). The successful deletion of the gene was confirmed by the significant reduction of Slc16a13 mRNA expression in KO mice compared to wild-type (WT) controls (Fig. 3b). Phenotypically, Slc16a13 KO mice exhibited normal growth and development, with no significant differences in body weight compared to their WT littermates.Fig. 3Generation of Slc16a13 KO mice.a Schematic illustration of Slc16a13 knockout mouse production by CRISPR/Cas-mediated genome engineering. Mouse Slc16a13 consists of 4 exons and spans 4.21 kb. The solid bars represent the ORF, and the open bars represent the UTRs. To generate a 3.33 kb deletion, exon 1 and exon 4 were selected as target sites for gRNA1 and gRNA2, respectively. Cas9 mRNA and gRNAs generated by in vitro transcription were co-injected into fertilized eggs for the production of Slc16a13 KO mice. The pups were genotyped by PCR followed by sequence analysis. b Expression of Slc16a13 in the E13.5 KO mouse embryo, liver, and kidney compared to wildtype. Data were presented as mean ± SD. The p value was determined by a two-sided unpaired Student’s t-test. KO Slc16a13 knockout mice, WT wild-type mice. Generation of Slc16a13 KO mice. a Schematic illustration of Slc16a13 knockout mouse production by CRISPR/Cas-mediated genome engineering. Mouse Slc16a13 consists of 4 exons and spans 4.21 kb. The solid bars represent the ORF, and the open bars represent the UTRs. To generate a 3.33 kb deletion, exon 1 and exon 4 were selected as target sites for gRNA1 and gRNA2, respectively. Cas9 mRNA and gRNAs generated by in vitro transcription were co-injected into fertilized eggs for the production of Slc16a13 KO mice. The pups were genotyped by PCR followed by sequence analysis. b Expression of Slc16a13 in the E13.5 KO mouse embryo, liver, and kidney compared to wildtype. Data were presented as mean ± SD. The p value was determined by a two-sided unpaired Student’s t-test. KO Slc16a13 knockout mice, WT wild-type mice. To assess metabolic function under stress, KO and WT mice were subjected to a forced treadmill running test, with blood analysis conducted at baseline (pre-exercise) and at 0, 50, and 90 min post-exercise (Fig. 4a). At baseline, there were no significant differences in blood glucose or lactate concentrations between the genotypes. The glucose level of KO mice (193.6 mg/dL) was comparable to that of wild-type mice (175.8 mg/dL) (Fig. 4b), and the lactic acid level in Slc16a13 KO mice (2.26 mmol/L) was not significantly different from that in wild-type mice (4.1 mmol/L) (Fig. 4c). Importantly, the exercise capacity of KO mice was not compromised, as their average running duration (53.78 min) was not significantly different from that of wild-type mice (54.73 min) (Fig. 4d).Fig. 4Mouse treadmill experiment and biochemical analysis.a Treadmill experiment protocol. Blood samples were collected at the following time points: 5 min before running and at 0, 50, and 90 min after completion. The blood lactate, glucose, plasma amino acids, and acylcarnitine profiles were analysed. b, c Blood lactate and glucose levels before running in Slc16a13 KO mice compared to wildtype. d Running duration of Slc16a13 KO mice (n = 5) compared to wildtype (n = 5). e, f Blood lactate and glucose levels at the designated time points in wild-type (n = 5) and KO mice (n = 5). Data were presented as mean ± SD. The p values were determined by two-sided unpaired Student’s t-test (b–e) or two-way ANOVA for multiple comparisons (e, f). KO Slc16a13 knockout mice, WT wild-type mice. Mouse treadmill experiment and biochemical analysis. a Treadmill experiment protocol. Blood samples were collected at the following time points: 5 min before running and at 0, 50, and 90 min after completion. The blood lactate, glucose, plasma amino acids, and acylcarnitine profiles were analysed. b, c Blood lactate and glucose levels before running in Slc16a13 KO mice compared to wildtype. d Running duration of Slc16a13 KO mice (n = 5) compared to wildtype (n = 5). e, f Blood lactate and glucose levels at the designated time points in wild-type (n = 5) and KO mice (n = 5). Data were presented as mean ± SD. The p values were determined by two-sided unpaired Student’s t-test (b–e) or two-way ANOVA for multiple comparisons (e, f). KO Slc16a13 knockout mice, WT wild-type mice. Following the exercise test, blood glucose levels remained comparable between KO and WT mice throughout the recovery period (Fig. 4e). However, the lactate kinetics were markedly different. As expected, WT mice showed a sharp, transient increase in blood lactate immediately after the run, which was efficiently declined over the 90-minute recovery period. Conversely, Slc16a13 KO mice displayed significantly exaggerated and sustained hyperlactatemia. The fold-increase in lactate was significantly higher in KO mice at all post-exercise time points (0, 50, and 90 min) compared to WT controls (Fig. 4f). This demonstrated impairment in lactate clearance in Slc16a13 KO mice following intensive exercise directly mirrors the clinical findings in our patient, providing strong functional evidence that loss of SLC16A13 function is responsible for the observed exercise-induced lactic acidemia. Altered amino acid profiles in Slc16a13 knockout mice recapitulate aspects of the patient’s metabolic phenotype To further investigate whether the loss of Slc16a13 affects other metabolic pathways, we analyzed the plasma amino acid and acylcarnitine profiles in both KO and WT mice before and after the exercise test. At baseline, the plasma amino acid profiles were significantly different between the genotypes. WT mice exhibited significantly higher concentrations of alanine (Ala), glycine (Gly), leucine (Leu), proline (Pro), tyrosine (Tyr), and valine (Val) compared to Slc16a13 KO mice (Fig. 5a).Fig. 5Plasma amino acid and acylcarnitine profiles of the mice.a Plasma amino acid of Slc16a13 KO mice (n = 5) measured before the treadmill experiment is compared with wildtype (n = 5). Comparison of plasma amino acid (b–g) and acylcarnitine (h–j) profiles of wildtype (n = 5) and Slc16a13 knockout mice (n = 5) at different running time points relative to before the treadmill experiment. The data were presented as mean ± SD. Data were presented as mean ± SD. The p values were determined by two-sided unpaired Student’s t-test (a) or two-way ANOVA with Dunnett’s multiple comparisons (b–f). KO Slc16a13 knockout mice, WT wild-type mice. Plasma amino acid and acylcarnitine profiles of the mice. a Plasma amino acid of Slc16a13 KO mice (n = 5) measured before the treadmill experiment is compared with wildtype (n = 5). Comparison of plasma amino acid (b–g) and acylcarnitine (h–j) profiles of wildtype (n = 5) and Slc16a13 knockout mice (n = 5) at different running time points relative to before the treadmill experiment. The data were presented as mean ± SD. Data were presented as mean ± SD. The p values were determined by two-sided unpaired Student’s t-test (a) or two-way ANOVA with Dunnett’s multiple comparisons (b–f). KO Slc16a13 knockout mice, WT wild-type mice. The response to exercise further highlighted these metabolic differences. In WT mice, the stress of running induced a significant decrease in the levels of Ala, Gly, Leu, Pro, Tyr, and Val during the recovery period, consistent with their utilization for energy production and gluconeogenesis (Fig. 5b–g). On the other hand, Slc16a13 KO mice displayed a divergent and abnormal response. Their Ala and Gly levels remained unchanged post-exercise. Furthermore, unlike the WT controls, the levels of the branched-chain amino acids (BCAAs) Leu and Val, as well as Pro and Tyr, were significantly increased following the run compared to their baseline levels. This suggests a potential impairment in their metabolic processing under stress conditions in the absence of SLC16A13. In contrast to the amino acid findings, the plasma acylcarnitine profiles, which reflect fatty acid oxidation, showed no significant differences between Slc16a13 KO and WT mice. Although the levels of short- (C0-C5) in KO mice trended to decrease compared to WT, medium- (C6-C12), and long-chain (C14-C18) acylcarnitines were comparable between the two groups, both before and after exercise (Fig. 5h–j). This suggests that the primary metabolic derangement in the KO mice is related to lactate and amino acid metabolism, rather than a global defect in fatty acid oxidation. Discussion In this study, we present the first compelling evidence linking biallelic, loss-of-function variants in the monocarboxylate transporter gene SLC16A13 to a distinct human disease phenotype. We have identified a novel homozygous frameshift variant, c.24delC p.(Asp9Thrfs*50), in a proband who presented initially with idiopathic short stature but was subsequently found to have a profound metabolic derangement characterized by exercise-induced lactic acidemia. The pathogenicity of this variant is strongly supported by its nature, a frameshift leading to a premature stop codon and a truncated, non-functional protein, and its segregation in the family consistent with autosomal recessive inheritance. Crucially, the functional consequence of this genetic defect was validated in a Slc16a13 knockout mouse model, which recapitulated the core clinical feature of impaired lactate clearance under physiological stress. Together, these convergent lines of evidence from human and animal studies allow us to define a new inborn error of metabolism rooted in defective lactate transport. The SLC16A comprises 14 members, with the monocarboxylate transporters (MCTs) 1–4 being the most extensively studied for their roles in the transport of lactate, pyruvate, and ketone bodies. SLC16A13, or MCT13, has remained comparatively enigmatic despite its high expression in metabolically critical tissues, including the liver, kidney, and colon. While genome-wide association studies (GWAS) had previously linked common variants near the SLC16A13 locus to an increased risk for type 2 diabetes in certain populations13, its role in Mendelian disease was unknown. Lactate is now understood not as a metabolic waste product, but as a key energy shuttle and a primary substrate for hepatic gluconeogenesis19. The liver is the principal site of lactate clearance from the blood circulation. Given SLC16A13’s high expression in the liver and its previously demonstrated function as a high-affinity lactate transporter in murine hepatocytes9,12, we hypothesized that its absence would critically impair the first step of the Cori cycle: the uptake of lactate from the blood into the liver. Our findings confirm that SLC16A13 is not redundant and plays an indispensable, non-compensated role in this process, particularly during periods of high lactate flux. A critical aspect of this investigation was the use of a standardized exercise test. At rest, the proband’s circulating lactate levels were within the normal range, effectively masking the underlying genetic defect. This observation explains why the metabolic disorder was not identified during routine clinical workups. Although the workload was fixed at 30 W for safety, continuous monitoring of hemodynamic and metabolic parameters, including blood pressure, heart rate, ECG, VO₂, VCO₂, VE, and tidal volume, demonstrated an adequate and compensated cardiopulmonary response. These normal ventilatory and gas exchange dynamics effectively rule out secondary hyperlactatemia driven by systemic hypoxia or respiratory insufficiency. Consequently, the pronounced upward trajectory of blood lactate (Fig. 2c) and the failure to achieve steady-state kinetics suggest a primary defect in lactate clearance, rather than acute lactate overproduction driven by physiological stress or tissue hypoxia. The resulting pattern, normal resting lactate with an exaggerated and prolonged rise post-exertion, is a classic hallmark of impaired lactate clearance. This pattern is similar to that observed in patients with mitochondriopathy (MCP), where resting lactate levels may be normal but increase significantly under exertion16. This delayed clearance suggests a possible impairment of the lactate shuttle. Notably, genetic variation in monocarboxylate transporter 1 (MCT1), a key lactate transporter, has been shown to influence lactate kinetics during recovery from high-intensity exercise20. These underscore the essential role of dynamic stress testing in the diagnostic algorithm for patients with unexplained exercise intolerance or suspected metabolic disorders, as baseline measurements can be deceptively normal. The comprehensive metabolic profiling of the proband and the KO mice allows us to propose a detailed mechanistic model. We posit that the primary defect is a severe impairment of SLC16A13-mediated lactate transport into hepatocytes, creating a bottleneck that prevents lactate from being efficiently converted to pyruvate and subsequently to glucose via gluconeogenesis. The inability to utilize lactate resulted in upregulating alternative gluconeogenic pathways. Elevated alanine levels in the proband, particularly post-exercise, suggest increased activity of the glucose-alanine (Cahill) cycle, wherein muscle-derived pyruvate is transaminated to alanine, transported to the liver, converted back to pyruvate for gluconeogenesis, with ammonia released as a byproduct. The transient rise in ammonia observed in the proband supports this metabolic shift. Under standard physiological conditions, brief and low-intensity exercise is not typically associated with significant GNG or muscle protein breakdown. However, we propose that the unique metabolic state of the proband, specifically the combination of a post-absorptive state and pathological lactate accumulation, might alter these typical kinetics. The proband was in a 6–8 hour fasting (NPO) state prior to the exercise challenge, a condition known to stimulate peripheral alanine production and accelerate hepatic GNG to maintain glycemic stability21. Consequently, the elevated baseline (R0) alanine levels likely reflect this fasting-induced shift. Furthermore, while the exercise intensity was low, the proband experienced a rapid, pathological rise in blood lactate, which is likely due to the SLC16A13 defect. Previous studies have demonstrated that acute lactate loading stimulates hepatic alanine uptake and enhances the conversion of alanine to glucose22. We hypothesize that this lactate-loading effect, combined with the observed rise in plasma ammonia, might indicate an early and compensatory recruitment of the Cahill cycle and amino acid catabolism, despite the low intensity of physical activity. Additionally, the significant post-exercise decrease in most acylcarnitine species in the proband indicates heightened fatty acid β-oxidation to meet exercise energy demands. This finding aligns with previous studies showing that Slc16a13 deletion in mice leads to AMPK activation and enhanced mitochondrial β-oxidation12, suggesting that when lactate cannot be efficiently utilized by the liver, the system compensates by increasing fat metabolism. In KO mice, the metabolic response might follow a different trajectory. While WT mice showed a decrease in alanine and branched-chain amino acids (BCAAs) during exercise (indicating efficient utilization), the KO mice exhibited stable alanine levels and an increase in BCAAs post-exercise. This rise in BCAAs, coupled with a downward trend in short-chain acylcarnitines (C0-C5), suggests a shift toward accelerated BCAA oxidation. The reduction in acylcarnitines, which are intermediates of BCAA catabolism, suggests that the flux through the BCAA-dehydrogenase complex is so high that these intermediates are rapidly oxidized in the mitochondria rather than being released into the circulation12,23,24. We propose that these divergences might be attributable to species-specific metabolic flexibility. Mice possess a significantly higher mass-specific metabolic rate than humans, which may necessitate a shift toward BCAA catabolism rather than the glucose-alanine cycle during acute stress25. While the proband was initially diagnosed with idiopathic short stature and partial IGF-1 deficiency, our findings raise the possibility that her growth impairment may be a secondary consequence of her underlying metabolic disorder. Chronic, even low-level, metabolic acidosis is a well-established contributor to growth failure in children26–29. The proposed mechanisms include the suppression of hepatic IGF-1 production, induction of growth hormone resistance at the tissue level, direct inhibition of protein synthesis, and activation of muscle proteolysis to buffer acidosis. It is plausible that recurrent, transient episodes of hyperlactatemia following physical activity over many years created a cumulative state of metabolic stress that ultimately blunted her growth potential. In contrast, the KO mice in our study were maintained in a controlled laboratory environment and were only subjected to acute, exercise-induced stress. This experimental design likely did not recapitulate the chronic, longitudinal metabolic stress required to manifest a growth phenotype in a murine model. The convergence of elevated lactate under stress, abnormal amino acid profiles, and reduced lactate clearance in both the proband and Slc16a13-deficient mice strongly supports the physiological relevance of this transporter in maintaining metabolic homeostasis. The primary limitation of this study is that its conclusions are drawn from a single human subject (n = 1). To firmly establish the full clinical spectrum and natural history of SLC16A13 deficiency, the identification and characterization of additional patients with pathogenic variants in this gene are essential. Secondly, although our data strongly implicate a defect in blood lactate clearance following a lactate stress test, the contribution of SLC16A13-expressing tissues involved in this process, such as the liver and kidney, was not directly evaluated in this study. Future studies using tissue-specific knockout mice or stable isotope tracer infusions could delineate the relative contributions of different organs to the observed phenotype. Finally, our mechanistic model, though well-supported, is inferential. Direct confirmation would require lactate transport assays in patient-derived cells, such as iPSC-differentiated hepatocytes, which would also provide a valuable platform for screening potential therapeutic compounds. In conclusion, this study provides the first report of a human disease caused by biallelic loss-of-function variants in SLC16A13. We have demonstrated that this gene is critical for systemic lactate homeostasis, and its deficiency leads to a clinically relevant phenotype of exercise-induced lactic acidemia. By integrating detailed clinical phenotyping with functional validation in a relevant animal model, we have delineated a novel inborn error of metabolism and proposed a detailed model of the resulting metabolic dysregulation. This discovery not only solves a diagnostic odyssey for one patient but also adds SLC16A13 to the growing list of genes implicated in metabolic disease and underscores the central, dynamic role of lactate in human energy metabolism. Methods Ethical approval The human study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Thailand (IRB No. 813/63). It was conducted following the Declaration of Helsinki (version 2002) and additional ethical requirements. Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC), Ethics Committee of Chulalongkorn University (No. 015/2565). The animals were cared for and utilized in accordance with the guidelines of the IACUC of Chulalongkorn University, following the Guide for the Care and Use of Laboratory Animals by the Institute for Laboratory Animal Research, National Research Council, USA. Human subject enrollment A patient (proband) suspected of having a metabolic disorder attended the genetic clinic, accompanied by a parent, and the patient’s brother was also enrolled in the study. Medical histories of the patient and family members were collected. A physical examination of the patient was conducted. Informed consent was obtained from all participants involved in this study, encompassing approval for both the publication of data and photographs. Genetic analysis Genomic DNA was isolated from peripheral blood leukocytes of the proband and family members. Genome sequencing was conducted using the DNBSEQ-T7 sequencer (MGI Tech Co., Ltd., China). The raw genome sequencing data were mapped against the human genome reference GRCh38 for variant discovery using GATK4.0. The variants were filtered using the following criteria: (1) passed the variant calling QC process, (2) had read depth >10 with variant read frequency >20%, (3) had allele frequency <5% in genome aggregation database (gnomAD) and exome sequencing project (ESP), (4) located in the coding regions and canonical splice sites of the genes without silence consequences, (5) predicted pathogenic (for missense variants) by in silico software, including SIFT, Polyphen2, MutationTaster, FATHMM, RAVEL, and BayesDel, (6) inherited in an autosomal recessive manner, X-linked recessive manner, or occurring de novo, (7) absent in the Thai Genome Reference Database (ThaiGeR) (https://thaiger.genomicsthailand.com) and in-house database of 3206 Thai exomes. The filtered variants were classified according to the American College of Medical Genetics and Genomics (ACMG) interpretation guidelines30. The variant was validated by Sanger sequencing using the forward primer: 5’-CTTCAGTCCTATATCGCCCCG-3’ and the reverse primer: 5’-CCGCACTCACTCCCAAACT-3’. Alignment of the conserved regions among different species comprising Homo sapiens (Human) NP_963860.1, Pan troglodytes (Chimpanzee) XP_511981.2, Sus scrofa (Pig) XP_003131974.1, Canis familiaris (Dog) XP_849442.1, Bos taurus (Bovine) NP_001069600.1, Mus musculus (Mouse) NP_758959.1, Danio rerio (Zebrafish) XP_001920250.2) was performed using Clustal Omega (version 1.2.4). Body composition measurement Body composition was assessed using Inbody770 (InBody Co., LTD, South Korea) according to the manufacturer's instruction. The subject was asked to be NPO for 6–8 h before the procedure. The measurements were taken at 30 impedance measurements, sic frequencies at each of the five segments (right arm (RA), left arm (LA), Trunk, right leg (RL), left leg (LL)). Lactate stress test To generate a lactate stress condition, an exercise stress test was performed as previously described16. Following a 10-min baseline rest and a 1-min unloaded warm-up, the subject performed 15 min of continuous cycling at a constant workload of 30 W on a pedal-rate-independent cycle ergometer (Corival CPET, Lode, The Netherlands). Throughout the protocol, cardiovascular parameters, including blood pressure, heart rate, and continuous electrocardiography (ECG), were monitored. Ventilatory and gas exchange data, including tidal volume (Vt), ventilation during exercise (VE), oxygen uptake (VO2), and carbon dioxide production (VCO2), were collected using the Ultima™ CardiO2® gas exchange analysis system (MGC Diagnostics, St. Paul, MN, USA). Serial blood sampling was performed at predefined intervals. Immediately post-exercise, the subject rested in a seated position for the recovery phase. Blood biochemistry analysis The patient was asked to be NPO for 6–8 h before the procedure. Blood samples were drawn from an indwelling catheter inserted into a dorsum vein of the hand at each time point as follows: after 10 min resting before the test (R0), after starting cycling for 5 min (S5), 10 min (S10) and 15 min (S15), and after finishing cycling for 15 min (R1) and 30 min (R2). Blood lactate was determined immediately after blood collection using the EDGE handheld blood lactate meter and EDGE blood lactate test strip (ApexBio, Taiwan). Blood samples were kept on ice and sent to the central laboratory where further biochemical blood analysis was performed including glucose, lactate, ammonia, creatine kinase (CK), blood urea nitrogen (BUN), creatinine, serum glutamic-oxaloacetic transaminase (SGOT), Serum glutamate-pyruvate transaminase (SGPT), electrolytes (Na, K, Cl, HCO3, and AGAP), cholesterol (CHOL), triglycerides (TRIG), high density lipoprotein (HDL), and low density lipoprotein (LDL). For plasma amino acid profile, the samples were analyzed using Biochrom 30+ Series amino acid analyzer (Harvard Bioscience, USA) or Tandem Mass Spectrometry (TMS) (Waters Corporation, USA). Whereas the acylcarnitine profile was performed by the TMS system of the Waters Corporation, according to the manufacturer’s protocol. Urine organic acid analysis Voided midstream urine was collected from the patient after 10 min resting before the cycling (R0) and after finishing cycling for 15 min (R1). Urine samples were analyzed using gas chromatography/mass spectrometry (GC/MS, Agilent Technologies Inc., USA). Generation of mutant mice Slc16a13 knockout (KO) mice on a C57BL/6NJ background were generated by Cyagen Biosciences Inc. (China) using CRISPR/Cas9-mediated genome editing (Fig. 3a). Following a 1-week acclimatization period, mice were housed individually in ventilated plastic cages within the animal facility. Environmental conditions were maintained at 24 ± 1 °C, relative humidity at 55 ± 10%, under a 12 h light/12 h dark photoperiod. Animals had ad libitum access to standard rodent chow and drinking water. In a separate experiment, mice were euthanized by an overdose of isoflurane, followed by cervical dislocation. Subsequently, embryonic day 13.5 (E13.5) mouse embryos, as well as liver and kidney tissues, were collected for the assessment of Slc16a13 expression. Total RNA was isolated using RNeasy Plus Kits (Qiagen), and complementary DNA (cDNA) was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad) in accordance with the manufacturer’s instructions. Slc16a13 transcript levels were quantified by real-time PCR employing gene-specific primers: forward, 5’-ACCTGAGTATTGGGCTGCTG-3’; reverse, 5’-CCATGGTCGGAGTGAAGGT-3’. For functional studies, 5- to 7-month-old mice were allocated into two experimental groups (n = 5 mice/group): wild-type (WT) and Slc16a13 KO (KO). Only female mice were included to match the biological sex of the proband. One week prior to the treadmill running experiment, mice underwent a 3-day adaptation protocol consisting of 3 min of restraint for blood collection and treadmill running at 10 m/min on a 10° incline. Treadmill running experiment in mice Mice were subjected to a treadmill running experiment (Model LE8710MTS; Panlab, Harvard apparatus) that was slightly modified from a previous study18. To generate anaerobic glycolysis associated with lactate accumulation, mice were forced to concentric exercise by running at a 15° elevation with an initial velocity of 6 m/min and an increase in speed of 2 m/min every 5 min until exhausting. Exhaustion was defined as the inability to stay off shock grids (100 V) for at least 5 s when the maximum running duration was recorded. Blood drawing and biochemical testing in mice Two hundred microliters (200 µL) of blood samples were obtained by lateral tail vein puncture at each time point as follows; 5 min before treadmill running, after finishing running for 0, 50, and 90 min. The blood lactate level was determined using the EDGE blood lactate meter and EDGE blood lactate test strip (ApexBio, Taiwan). The blood glucose was measured using an Alphatrak 2 glucose meter and an Alphatrak 2 test strip (Zoetis, US). Plasma amino acid and acylcarnitine profiles were analyzed using TMS. Statistical analysis No power calculation was performed to determine the sample size. The sample size for each group was assigned based on a previous study31. All data are presented as means ± SD. An unpaired two-tailed Student’s t-test was performed to analyze normally distributed data between genotypes. A two-way ANOVA with Dunnett’s multiple comparisons test to assess differences between time points. All statistical analyses were conducted using GraphPad Prism 8 software. Statistical significance is defined as a p value ≤0.05. Supplementary information Supplementary Information_8Apr2026. Supplementary Information_8Apr2026.